Kent James Weinhold, PhD

Print

email this


Professor of Surgery
Professor of Immunology
Professor in Pathology
Chief, Division of Surgical Sciences
Department / Division:
Surgery / Surgical Sciences
Address:
204 Surg Oncol Res Fac
Durham, NC 27710
Office Telephone:
(919) 684-5572
Training:
  • PhD, Thomas Jefferson University, 1979
Research Interests:

In summary, the Weinhold laboratory has established a broad translational scientific interest as well as a number of key tools to identify immunologic signatures that predict disease outcomes in a wide variety of human diseases.  Even at this very early stage of evaluation, these highly standardized and validated assay platforms have proven tremendously valuable in monitoring clinical trials of HIV/AIDS vaccine candidates as well as novel anti-cancer therapies. This versatility, as well as the quantitative and qualitative assessments of immune reactivity that they provide, makes them ideal vehicles for future identification of biomarkers and immunologic signatures gleaned in the context of novel new therapeutic interventions.  This team, therefore, is well positioned to contribute their extensive expertise and knowledge base in this area to the design, implementation, and evaluation of new therapies that are currently in development.

Representative Publications:
  • Freel, SA; Lamoreaux, L; Chattopadhyay, PK; Saunders, K; Zarkowsky, D; Overman, RG; Ochsenbauer, C; Edmonds, TG; Kappes, JC; Cunningham, CK; Denny, TN; Weinhold, KJ; Ferrari, G; Haynes, BF; Koup, RA; Graham, BS; Roederer, M; Tomaras, GD. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. Journal of Virology. 2010;84:4998-5006.  Abstract
  • Goonetilleke, N; Liu, MK; Salazar-Gonzalez, JF; Ferrari, G; Giorgi, E; Ganusov, VV; Keele, BF; Learn, GH; Turnbull, EL; Salazar, MG; Weinhold, KJ; Moore, S; CHAVI Clinical Core B, ; Letvin, N; Haynes, BF; Cohen, MS; Hraber, P; Bhattacharya, T; Borrow, P; Perelson, AS; Hahn, BH; Shaw, GM; Korber, BT; McMichael, AJ. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine. 2009;206:1253-1272.  Abstract
  • Murdoch, DM; Suchard, MS; Venter, WD; Mhlangu, P; Ottinger, JS; Feldman, C; Van Rie, A; Glencross, DK; Stevens, WS; Weinhold, KJ. Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). AIDS Research and Therapy. 2009;6:16.  Abstract
  • Shen, X; Parks, RJ; Montefiori, DC; Kirchherr, JL; Keele, BF; Decker, JM; Blattner, WA; Gao, F; Weinhold, KJ; Hicks, CB; Greenberg, ML; Hahn, BH; Shaw, GM; Haynes, BF; Tomaras, GD. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. Journal of Virology. 2009;83:3617-3625.  Abstract
  • Spearman, P; Kalams, S; Elizaga, M; Metch, B; Chiu, YL; Allen, M; Weinhold, KJ; Ferrari, G; Parker, SD; McElrath, MJ; Frey, SE; Fuchs, JD; Keefer, MC; Lubeck, MD; Egan, M; Braun, R; Eldridge, JH; Haynes, BF; Corey, L; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27:243-249.  Abstract
  • Alam, SM; Scearce, RM; Parks, RJ; Plonk, K; Plonk, SG; Sutherland, LL; Gorny, MK; Zolla-Pazner, S; Vanleeuwen, S; Moody, MA; Xia, SM; Montefiori, DC; Tomaras, GD; Weinhold, KJ; Karim, SA; Hicks, CB; Liao, HX; Robinson, J; Shaw, GM; Haynes, BF. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. Journal of Virology. 2008;82:115-125.  Abstract
  • Gasper-Smith, N; Crossman, DM; Whitesides, JF; Mensali, N; Ottinger, JS; Plonk, SG; Moody, MA; Ferrari, G; Weinhold, KJ; Miller, SE; Reich, CF; Qin, L; Self, SG; Shaw, GM; Denny, TN; Jones, LE; Pisetsky, DS; Haynes, BF. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of Virology. 2008;82:7700-7710.  Abstract
  • Gorse, GJ; Baden, LR; Wecker, M; Newman, MJ; Ferrari, G; Weinhold, KJ; Livingston, BD; Villafana, TL; Li, H; Noonan, E; Russell, ND; HIV Vaccine Trials Network. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine. 2008;26:215-223.  Abstract
  • Russell, ND; Graham, BS; Keefer, MC; McElrath, MJ; Self, SG; Weinhold, KJ; Montefiori, DC; Ferrari, G; Horton, H; Tomaras, GD; Gurunathan, S; Baglyos, L; Frey, SE; Mulligan, MJ; Harro, CD; Buchbinder, SP; Baden, LR; Blattner, WA; Koblin, BA; Corey, L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2007;44:203-212.  Abstract
  • Mulligan, MJ; Russell, ND; Celum, C; Kahn, J; Noonan, E; Montefiori, DC; Ferrari, G; Weinhold, KJ; Smith, JM; Amara, RR; Robinson, HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Research and Human Retroviruses. 2006;22:678-683.  Abstract
  • Betts, MR; Exley, B; Price, DA; Bansal, A; Camacho, ZT; Teaberry, V; West, SM; Ambrozak, DR; Tomaras, G; Roederer, M; Kilby, JM; Tartaglia, J; Belshe, R; Gao, F; Douek, DC; Weinhold, KJ; Koup, RA; Goepfert, P; Ferrari, G. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proceedings of the National Academy of Sciences of USA. 2005;102:4512-4517.  Abstract
  • Kaplan, SS; Ferrari, G; Wrin, T; Hellmann, NS; Tomaras, GD; Gryszowka, VE; Fiscus, SA; Weinhold, KJ; Hicks, CB. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Research and Human Retroviruses. 2005;21:13-16.  Abstract
  • Ferrari, G; Currier, JR; Harris, ME; Finkelstein, S; de Oliveira, A; Barkhan, D; Cox, JH; Zeira, M; Weinhold, KJ; Reinsmoen, N; McCutchan, F; Birx, DL; Osmanov, S; Maayan, S. HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. Human Immunology. 2004;65:648-659.  Abstract
  • Ferrari, G; Neal, W; Ottinger, J; Jones, AM; Edwards, BH; Goepfert, P; Betts, MR; Koup, RA; Buchbinder, S; McElrath, MJ; Tartaglia, J; Weinhold, KJ. Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. Journal of Immunology. 2004;173:2126-2133.  Abstract
  • Montefiori, DC; Metch, B; McElrath, MJ; Self, S; Weinhold, KJ; Corey, L; HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. Journal of Infectious Diseases. 2004;190:1962-1969.  Abstract
  • Wright, PF; Mestecky, J; McElrath, MJ; Keefer, MC; Gorse, GJ; Goepfert, PA; Moldoveanu, Z; Schwartz, D; Spearman, PW; El Habib, R; Spring, MD; Zhu, Y; Smith, C; Flores, J; Weinhold, KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. Journal of Infectious Diseases. 2004;189:1221-1231.  Abstract
  • Sufka, SA; Ferrari, G; Gryszowka, VE; Wrin, T; Fiscus, SA; Tomaras, GD; Staats, HF; Patel, DD; Sempowski, GD; Hellmann, NS; Weinhold, KJ; Hicks, CB. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. Journal of Infectious Diseases. 2003;187:1027-1037.  Abstract
  • Demarest, JF; Jack, N; Cleghorn, FR; Greenberg, ML; Hoffman, TL; Ottinger, JS; Fantry, L; Edwards, J; O'Brien, TR; Cao, K; Mahabir, B; Blattner, WA; Bartholomew, C; Weinhold, KJ. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. AIDS Research and Human Retroviruses. 2001;17:1333-1344.  Abstract